Paradigm Biopharmaceuticals

What Paradigm Biopharmaceuticals does

Paradigm Biopharmaceuticals Limited (ASX: PAR) is a Melbourne-headquartered, late-stage clinical biopharmaceutical company founded in 2014 to repurpose the semi-synthetic drug pentosan polysulfate sodium (PPS) for inflammatory, musculoskeletal and lysosomal-storage indications. The company is publicly listed on the Australian Securities Exchange and operates clinical infrastructure across Australia, the United States and Brazil, with offices in the EU and US supporting late-stage development.

The core asset is injectable PPS (brand: Zilosul), being advanced through Phase 3 clinical development (the 466-patient PARA_OA_012 trial, 140 sites) for knee and hip osteoarthritis, where it targets an addressable population of more than 72 million patients across the USA, EU5, Australia and Canada. The drug exerts a multi-mechanism action—blocking cartilage-degrading enzymes (ADAMTS-4, ADAMTS-5, MMP-3), reducing NF-kB-mediated inflammation, lowering NGF-driven pain, clearing GAG accumulation and improving subchondral microcirculation—giving it potential as a disease-modifying OA therapy rather than a purely symptomatic one. Beyond osteoarthritis, the pipeline includes Phase 2 programmes in MPS I and MPS VI (both FDA and EMA Orphan Drug Designations), earlier programmes in alphavirus-induced arthralgia (RRV/CHIKV), chronic heart failure (HFpEF) and ARDS, and a nasal-PPS franchise (Rhinosul) where a Phase 2a in allergic rhinitis missed its primary endpoint. The FDA granted Fast Track Designation for Zilosul in January 2022 and cleared the IND in October 2021.

Paradigm is pre-revenue and monetises only through equity capital and partnership optionality. Manufacturing is governed by a 25-year exclusive supply and licence agreement with Bene PharmaChem, the sole FDA-approved PPS manufacturer, and the company holds an exclusive 2018 licence covering PPS use in seven lysosomal storage diseases across the US, Japan, Europe, Australia and New Zealand. Commercialisation of Zilosul is planned either directly or via global/regional partners once Phase 3 data and FDA approval are secured, with management operating from a lean 11–50 employee base funded through repeated equity raises (latest rounds include A$5.0M from Obsidian Global Partners in November 2025 and approximately A$10.1M in April 2026).

Name

Paradigm Biopharmaceuticals

Legal name

Paradigm Biopharmaceuticals Limited

Website

https://paradigmbiopharma.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Paradigm Biopharmaceuticals (ASX: PAR) is a Melbourne-based clinical-stage biopharma developing injectable pentosan polysulfate sodium (Zilosul) for osteoarthritis and other inflammatory conditions. It is running a 466-patient Phase 3 OA trial under FDA Fast Track Designation and targeting a 72M+ patient market.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Drug repurposing therapeutics
• Osteoarthritis drug development
• Pentosan polysulfate sodium
• Mucopolysaccharidosis treatment
• Biopharmaceutical clinical pipeline

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Zilosul Commercialisation: Once FDA approval is obtained, Paradigm plans to commercialise Zilosul (injectable PPS) for osteoarthritis treatment. Revenue will come from product sales targeting the 72M+ patient addressable market in key markets (US, EU5, AU, CAN). The company is exploring strategic partnerships for global or regional commercialisation.
2. MPS Pipeline Products: Paradigm is developing PPS for Mucopolysaccharidosis I and VI (orphan diseases) with Phase 2 clinical trials. Orphan Designations in USA and EU provide potential for faster processing, regulatory support, and longer market exclusivity periods.
3. Licensing and Partnership Deals: Paradigm has entered into exclusive license agreements for PPS to treat lysosomal storage diseases including MPS (types I, II, III, IV, VI, VII), Gaucher and Fabry diseases. The company is open to strategic partnerships for commercialisation.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Paradigm Biopharmaceuticals is a late-stage drug development company focused on repurposing pentosan polysulfate sodium (PPS) — an FDA-approved drug with a 60-year safety record — into new therapeutic indications. Its lead product Zilosul® (injectable PPS) is in Phase 3 clinical trials as a disease-modifying treatment for osteoarthritis (OA). The company is also developing PPS for orphan indications including MPS I, MPS VI, alphavirus-induced arthritis, heart failure, ARDS, and allergic rhinitis.

Product overview

Paradigm Biopharmaceuticals Ltd is a late-stage drug development company focused on repurposing pentosan polysulfate sodium (PPS), an FDA-approved drug with a 60-year track record of safely treating inflammation. The company's lead commercial product is Zilosul® (injectable PPS) for osteoarthritis treatment, currently in Phase III clinical trials. Beyond osteoarthritis, Paradigm is developing PPS for multiple indications including mucopolysaccharidosis types I and VI (MPS I, MPS VI), alphavirus-induced arthritis (RRV/CHIKV), heart failure (HF), acute respiratory distress syndrome (ARDS), and allergic rhinitis (AR). The company also holds the trademark Rhinosul® for PPS commercialization. Paradigm operates with strategic partnerships for manufacturing (Bene PharmaChem) and has received FDA Fast Track designation and Orphan Drug designations for MPS I and VI in both the USA and EU.

Differentiator

Problem solved

Functional benefit

Brands

• Zilosul®: Registered trademark for injectable pentosan polysulfate sodium (iPPS) for the treatment of osteoarthritis.
• Rhinosul®

Products and services

• Zilosul® (injectable PPS for Osteoarthritis) Injectable pentosan polysulfate sodium (iPPS) being developed as a disease-modifying treatment for knee and hip osteoarthritis, targeting over 72 million patients in the USA, EU5, Australia, and Canada. Addresses inflammation, pain, and cartilage regeneration simultaneously with FDA Fast Track Designation granted in January 2022.
• PPS for MPS VI Investigational treatment for Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome) targeting bone and joint manifestations, chronic pain, and physical disability persisting despite enzyme replacement therapy.
• PPS for MPS I Investigational treatment for Mucopolysaccharidosis Type I (Hurler, Scheie, Hurler-Scheie syndromes) targeting residual musculoskeletal symptoms and chronic pain in patients who have received enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT).
• PPS for Alphavirus-induced Arthritis (RRV/CHIKV) Investigational treatment for joint function, mobility, and pain in patients with alphavirus-induced arthralgia such as Ross River virus and Chikungunya.
• PPS for Heart Failure (HFpEF) Preclinical-stage program investigating pentosan polysulfate sodium for treating chronic heart failure, particularly HFpEF (heart failure with preserved ejection fraction).
• PPS for Acute Respiratory Distress Syndrome (ARDS) Investigational program targeting ARDS via anti-inflammatory effects, inhibition of complement activation, and inhibition of ADAMTS-4 activity involved in adverse tissue remodelling.
• PPS for Allergic Rhinitis (Rhinosul®) Intranasal PPS spray (Rhinosul® trademark) developed for allergic rhinitis (hay fever). Phase 2a study completed but did not meet primary clinical endpoints; second-generation PPS molecules being considered.

Quantifiable outcome

• Phase III PARA_OA_012 trial enrolling 466 patients with interim analysis expected mid-2026
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Bene PharmaChemcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2018Paradigm has a longstanding relationship with Bene PharmaChem, the only FDA-approved manufacturer/supplier of PPS. Paradigm has an exclusive supply and licence agreement with Bene PharmaChem extending for 25 years post-registration, covering all markets and ensuring scalable manufacturing capabilities for iPPS clinical trials and commercialisation.
• Licensor for MPS/ LSD TreatmentcoreOEM/ Whitelabel/ Licensing PartnerParadigm entered into an exclusive license agreement in 2018 for the use of PPS to treat lysosomal storage diseases (LSDs) including MPS (types I, II, III, IV, VI, VII), Gaucher and Fabry diseases. The licensing agreement and accompanying Phase 2a human data adds valuable pipeline assets and IP portfolio protection.
• Dr Roberto Giugliani / Federal University of Rio Grande do SulminorStrategic or Co-development PartnerLead investigator for PARA_MPSVI_001 Phase 2 clinical trial in Brazil, supported by Dr Paula Frassinetti Vasconcelos de Medeiros from Federal University of Campina Grande.
• Adelaide Women's and Children's HospitalminorStrategic or Co-development PartnerClinical trial site for PARA_MPSI_001 open-label single-centre pilot study assessing PPS in MPS I patients who have received ERT and/or HSCT.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BioMarin Pharmaceutical: Global rare disease biotech with the dominant MPS franchise (Naglazyme for MPS VI, Vimizim for MPS IVA). BioMarin is the most directly comparable competitor in Paradigm's MPS I and MPS VI development programs and is the established benchmark for orphan LSD commercialization.
• Flexion Therapeutics: Developer of Zilretta, an intra-articular injection for knee osteoarthritis pain. Flexion is the most direct comparator on Zilosul's product profile (intra-articular OA injectables), with comparable patient populations, regulatory pathway, and specialty commercial model.
• Ultragenyx Pharmaceutical: Rare disease biotech commercializing therapies for MPS and other LSDs. Comparable business model to Paradigm's MPS pipeline, particularly the orphan commercialization strategy, US/EU regulatory approvals, and specialty distribution.
• Mesoblast: Australian-listed (ASX:MSB) cell therapy biotech with late-stage trials in inflammatory conditions. Multiple Paradigm executives (including Founder/Chairman Paul Rennie and CMO Donna Skerrett) held senior roles at Mesoblast, and the two companies share a closely comparable ASX small-cap biotech profile focused on musculoskeletal indications.
• Anika Therapeutics: Specialty OA franchise built on hyaluronic-acid intra-articular injections (Monovisc, Orthovisc, Cingal). Overlaps with Zilosul on product category, target patient population (knee OA), and intra-articular administration route.
• Bioventus: Orthopedic-focused company with dual pharmaceutical (hyaluronic acid OA injectables) and device franchises. Comparable on the intersection of intra-articular OA therapies and orthopedic distribution/clinical relationships.

Broad incumbents

• Pacira BioSciences: Larger non-opioid pain and orthobiologics specialist that acquired Flexion Therapeutics (Zilretta) in 2021. Comparable on the OA intra-articular injectable category and broader musculoskeletal-pain commercial footprint.

Regional players

• Starpharma Holdings: Australian-listed (ASX:SPL) late-stage biotech with multiple development programs. Comparable as a fellow ASX-listed small-cap biotech with global regulatory ambitions and several of Paradigm's regulatory team (e.g., Dr Karla Knower) coming from Starpharma.
• Immuron: Australian-listed (ASX:IMC) small-cap biotech with early commercial revenue. Paradigm NED Amos Meltzer currently leads Immuron, providing direct corporate overlap; comparable as a fellow ASX-listed biotech facing similar funding and commercialization dynamics.

Emerging players

• REGENXBIO: Clinical-stage biotech working across rare disease categories with novel modalities. Comparable on the early-stage commercialization challenge for high-value orphan indications, including working with LSD patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/paradigmbio
• Facebookfacebook.com/ParadigmPPS
• LinkedInlinkedin.com/company/paradigm-biopharmaceuticals

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paradigm Biopharmaceuticals